Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varenicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 10/20 | 0.71 |
| ▸ | CHRNA4 known ✓ | P43681 | 10/20 | 0.71 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.71 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.71 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.71 |
| ▸ | CHRNG | P07510 | 2/20 | 0.71 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.71 |
| ▸ | CHRND | Q07001 | 2/20 | 0.71 |
| ▸ | ESR1 | P03372 | 1/20 | 0.71 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.71 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.71 |
| ▸ | HTR3A | P46098 | 1/20 | 0.71 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varenicline SCHEMBL224851 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL31413925 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29761223 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL22323984 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL224852 | 1.00 | CHRNB2 (0.71) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL23510345 | 0.88 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL137144 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL5959022 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL225687 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| Varenicline SCHEMBL29710884 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249508-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2022-08-11 | — | — | US | claimed |
| CN-119104658-A | Method for detecting valicarb-isopropyl tartrate genotoxic impurity D | 山东百诺医药股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2023-09-14 | — | — | US | disclosed |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | ENDO OPERATIONS LIMITED (IE) | 2023-09-14 | — | — | US | disclosed |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11602537-B2 | Varenicline compound and process of manufacture thereof | PAR PHARMACEUTICAL, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| US-20220249508-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285407-A1 | VARENICILINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
| US-20220249508-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-11717524-B1 | Varenicline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-11602537-B2 | Varenicline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-20230285404-A1 | VARENICLINE COMPOUND AND PROCESS OF MANUFACTURE THEREOF | COMT, CYP2C9, CYP3A7 | CHRNB2 49/4885CHRNA4 41/4885CHRNB4 43/4885 |
| US-11872234-B2 | Vareniciline compound and process of manufacture thereof | COMT, CYP2C9, CYP3A7 | CHRNB2 88/4885CHRNA4 82/4885CHRNB4 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.